Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary

ARCALYST revenue growth of 62% for full-year 2025 was primarily driven by the expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment immediately following NSAID and colchicine failure. Management attributes commercial success to a fundamental shift in the treatment paradigm, supported by the 2025 ACC clinical guidance which ratified IL-1 inhibition as a preferred second-line approach. The company is leveraging its profitable ARCALYST franchise to fund strategic investments in ...